Protalix BioTherapeutics, Inc.
PLX
AMEX·Healthcare·Biotechnology·Mkt cap $215.1M
$2.67
▲ +2.10%
P/E
11.07
Mkt Cap
$215.1M
52-Wk Range
$1.53–$3.19
52-Week Range
$1.53 - $3.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 69.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary ProCellEx plant cell expression system enabling lower production costs and faster manufacturing
- Established partnerships with major pharmaceutical companies (Pfizer, Chiesi Farmaceutici) and research institutions (Fiocruz)
- Focused portfolio targeting underserved rare disease markets with limited competition and high unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Advancement of PRX-102 through late-stage clinical trials for Fabry disease, a significant rare disease market
Value
Undervalued - trading well below sector peers
Momentum
Hot
+36.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PLX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of $0.05 vs -$0.01 consensus (+600.0% surprise). Revenue of $19.9M vs $12.9M expected (+53.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+600.0%
Revenue trend · last 8Q
—
+74%
+170%
+16%
-1%
-50%
+234%
+27%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$18.0M
$18.2M
$10.1M
$15.7M
$17.9M
$9.1M
$33.8M
$19.9M
Margins · last 8Q
Gross
61.0%
Operating
23.5%
Profit
19.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · Aug 13, 2026
vs Industry
How PLX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.